389 related articles for article (PubMed ID: 31902355)
1. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.
Akıncıoğlu H; Gülçin İ
Mini Rev Med Chem; 2020; 20(8):703-715. PubMed ID: 31902355
[TBL] [Abstract][Full Text] [Related]
2. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.
Singh M; Kaur M; Kukreja H; Chugh R; Silakari O; Singh D
Eur J Med Chem; 2013; 70():165-88. PubMed ID: 24148993
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
4. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!
Tabet N
Age Ageing; 2006 Jul; 35(4):336-8. PubMed ID: 16788077
[TBL] [Abstract][Full Text] [Related]
5. Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents.
Pourshojaei Y; Eskandari K; Asadipour A
Mini Rev Med Chem; 2019; 19(19):1577-1598. PubMed ID: 31538893
[TBL] [Abstract][Full Text] [Related]
6. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.
Muñoz-Torrero D
Curr Med Chem; 2008; 15(24):2433-55. PubMed ID: 18855672
[TBL] [Abstract][Full Text] [Related]
7. Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.
Giménez-Llort L; Ratia M; Pérez B; Camps P; Muñoz-Torrero D; Badia A; Clos MV
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):124-131. PubMed ID: 28125507
[TBL] [Abstract][Full Text] [Related]
8. In silico methods to assist drug developers in acetylcholinesterase inhibitor design.
Bermúdez-Lugo JA; Rosales-Hernández MC; Deeb O; Trujillo-Ferrara J; Correa-Basurto J
Curr Med Chem; 2011; 18(8):1122-36. PubMed ID: 21291371
[TBL] [Abstract][Full Text] [Related]
9. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.
Rees TM; Brimijoin S
Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110
[TBL] [Abstract][Full Text] [Related]
10. Old and new acetylcholinesterase inhibitors for Alzheimer's disease.
Galimberti D; Scarpini E
Expert Opin Investig Drugs; 2016 Oct; 25(10):1181-7. PubMed ID: 27459153
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Son M; Park C; Rampogu S; Zeb A; Lee KW
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
[TBL] [Abstract][Full Text] [Related]
12. Tacrine derivatives and Alzheimer's disease.
Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C
Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341
[TBL] [Abstract][Full Text] [Related]
13. AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.
Wang Y; Wang H; Chen HZ
Curr Neuropharmacol; 2016; 14(4):364-75. PubMed ID: 26786145
[TBL] [Abstract][Full Text] [Related]
14. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.
Tamimi I; Ojea T; Sanchez-Siles JM; Rojas F; Martin I; Gormaz I; Perez A; Dawid-Milner MS; Mendez L; Tamimi F
J Bone Miner Res; 2012 Jul; 27(7):1518-27. PubMed ID: 22467182
[TBL] [Abstract][Full Text] [Related]
16. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents.
Pandey S; Singh BK
Curr Comput Aided Drug Des; 2020; 16(1):54-72. PubMed ID: 30827255
[TBL] [Abstract][Full Text] [Related]
17. Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors.
Saxena M; Dubey R
Curr Top Med Chem; 2019; 19(4):264-275. PubMed ID: 30706815
[TBL] [Abstract][Full Text] [Related]
18. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease.
Chierrito TPC; Pedersoli-Mantoani S; Roca C; Requena C; Sebastian-Perez V; Castillo WO; Moreira NCS; Pérez C; Sakamoto-Hojo ET; Takahashi CS; Jiménez-Barbero J; Cañada FJ; Campillo NE; Martinez A; Carvalho I
Eur J Med Chem; 2017 Oct; 139():773-791. PubMed ID: 28863358
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
McHardy SF; Wang HL; McCowen SV; Valdez MC
Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
[TBL] [Abstract][Full Text] [Related]
20. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease.
Rodrigues Simões MC; Dias Viegas FP; Moreira MS; de Freitas Silva M; Riquiel MM; da Rosa PM; Castelli MR; dos Santos MH; Soares MG; Viegas C
Mini Rev Med Chem; 2014 Jan; 14(1):2-19. PubMed ID: 24251806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
